MedTrace Logo

Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion

NCT04140448 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2023-10-18

No results posted yet for this study

Summary

This study mainly observed the ischemic index and vascular leakage index changes on ultra-wide field fluorescence angiography after anti-VEGF treatment , and whether these changes correlated with treatment efficacy in patients with macular edema secondary to retinal vein occlusion.

Conditions

  • Retinal Vein Occlusion
  • Macular Edema

Interventions

DRUG

Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]

Intravitreal injection of Ranibizumab 0.5 MG/0.05 ML

DEVICE

Ultra-wide Fluorescein Angiography

Ultra-wide-field Fluorescein Angiography can clearly observe the peripheral retina

Sponsors & Collaborators

  • Renmin Hospital of Wuhan University

    lead OTHER

Principal Investigators

  • CZ Chen, PHD · Renmin Hospital of Wuhan University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-09
Primary Completion
2024-10-30
Completion
2025-12-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04140448 on ClinicalTrials.gov